Daiichi Sankyo Initiates Overseas Phase III For NSCLC Drug
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and ArQule initiated patient enrollment for a Phase III trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer who have received one or two prior systemic anti-cancer therapies